Glucagon (9C1) Monoclonal Antibody

$Lane 1: HepG2; Lane 2: HT-29 lysate at 20 \u00b5g per lane, probed with bsm-51090M Glucagon (329CT36.10.10) Monoclonal Antibody at 1:1000 dilution and 4\u2103 overnight incubation, followed by secondary antibody incubation for 60min at room temperature.$

Lane 1: HepG2; Lane 2: HT-29 lysate at 20 \u00b5g per lane, probed with bsm-51090M Glucagon (329CT36.10.10) Monoclonal Antibody at 1:1000 dilution and 4\u2103 overnight incubation, followed by secondary antibody incubation for 60min at room temperature.

Applications

Reactivity

Human

Overview
Catalog #	bsm-51090M
Product Name	Glucagon (9C1) Monoclonal Antibody
Applications	WB
Reactivity	Human
Specifications
Conjugation	Unconjugated
Host	Mouse
Source	This Glucagon antibody is generated from mice immunized with a KLH conjugated synthetic peptide between 119-148 amino acids from human Glucagon.
Clonality	Monoclonal
Clone #	9C1
Isotype	IgG1
Concentration	0.5ug/ul
Purification	Purified monoclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein G column, eluted with high and low pH buffers and neutralized immediately, followed by dialysis against PBS.
Storage Buffer	0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Storage Condition	Store at -20°C for 12 months.
Target
Gene ID	2641
Swiss Prot	P01275
Synonyms	GLP1; GLP2; GRPP; Glucagon; GCG
Background	Glucagon plays a key role in glucose metabolism and homeostasis. Regulates blood glucose by increasing gluconeogenesis and decreasing glycolysis. A counterregulatory hormone of insulin, raises plasma glucose levels in response to insulin-induced hypoglycemia. Plays an important role in initiating and maintaining hyperglycemic conditions in diabetes. GLP-1 is a potent stimulator of glucose-dependent insulin release. Play important roles on gastric motility and the suppression of plasma glucagon levels. May be involved in the suppression of satiety and stimulation of glucose disposal in peripheral tissues, independent of the actions of insulin. Have growth-promoting activities on intestinal epithelium. May also regulate the hypothalamic pituitary axis (HPA) via effects on LH, TSH, CRH, oxytocin, and vasopressin secretion. Increases islet mass through stimulation of islet neogenesis and pancreatic beta cell proliferation. Inhibits beta cell apoptosis. GLP-2 stimulates intestinal growth and up-regulates villus height in the small intestine, concomitant with increased crypt cell proliferation and decreased enterocyte apoptosis. The gastrointestinal tract, from the stomach to the colon is the principal target for GLP-2 action. Plays a key role in nutrient homeostasis, enhancing nutrient assimilation through enhanced gastrointestinal function, as well as increasing nutrient disposal. Stimulates intestinal glucose transport and decreases mucosal permeability. Oxyntomodulin significantly reduces food intake. Inhibits gastric emptying in humans. Suppression of gastric emptying may lead to increased gastric distension, which may contribute to satiety by causing a sensation of fullness. Glicentin may modulate gastric acid secretion and the gastro-pyloro-duodenal activity. May play an important role in intestinal mucosal growth in the early period of life.
Application Dilution
WB	1:300-5000